Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance

Simply Wall St.

Mar 03

AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2616313728"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616313728\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616313728?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-03 12:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616313728","market":"us","top_or_hot":-1,"title":"Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast (ASX:MSB) Valuation After Earnings Update And New Ryoncil Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 12:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB","symbol_name":"美莎比信托","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo","article_id":"2616313728","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-after-earnings-update-and-new-ryo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616313728","pubTimestamp":1772513408,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Mesoblast’s latest guidance matters for shareholders\nMesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations.\nThe company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million.\nSee our latest analysis for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MSB":"美莎比信托","MSB.AU":"MESOBLAST LTD"},"translate_title":"Mesoblast(ASX：MSB)盈利更新和新Ryoncil收入指引后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1.5,"MSB":1.5},"content_text":"AdvertisementWhy Mesoblast’s latest guidance matters for shareholders Mesoblast (ASX:MSB) has just paired a detailed half year earnings update with new revenue guidance for its key product Ryoncil, giving investors fresh numbers on both recent performance and management expectations. The company reported half year revenue of US$51.34 million and a net loss of US$40.16 million, and now forecasts full year 2026 Ryoncil net revenue between US$110 million and US$120 million. See our latest analysis for Mesoblast. Despite the fresh Ryoncil guidance and sharp increase in reported half year revenue, Mesoblast’s recent share price performance has been weak. The 30 day share price return shows an 18.18% decline and the year to date share price return shows a 25.27% decline. Over three years, the total shareholder return is around 2.4x, while the one year total shareholder return shows a 17.53% decline, suggesting long term holders have seen sizable gains but more recent momentum has faded. If Mesoblast’s volatility has you reassessing where you look for ideas, this could be a good moment to scan our list of 10 healthcare AI stocks as another way to research market opportunities. With Mesoblast shares showing weak recent returns, despite new Ryoncil revenue guidance and a price that sits well below some analyst targets, you have to ask: is this a mispriced growth story, or is the market already looking ahead? Most Popular Narrative: 46% Undervalued Mesoblast’s most followed valuation narrative puts fair value at A$3.83 per share, compared with the last close of A$2.07, so the gap between price and expectations is wide.  The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption. This would be most visible in revenue growth and operating leverage.  Read the complete narrative. Want to know what kind of revenue ramp and margin shift sits behind that fair value, and how long it is assumed to take? The narrative leans on aggressive top line expansion, a sharp swing in profitability and a valuation multiple usually linked with mature growth leaders. Curious which numbers have to line up for A$3.83 to make sense? Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on key risks, including slower than expected Ryoncil uptake relative to the current cash burn and potential delays or setbacks in the planned label expansions. Find out about the key risks to this Mesoblast narrative. Another View: High P/S Ratio Raises Questions The first valuation leans on fast revenue growth and future profitability, but today Mesoblast trades on a P/S ratio of 28.9x, which is well above the Australian Biotechs average of 17.1x, peers at 17.6x, and a fair ratio of 4.8x. If growth or margins slip, how much room is there for disappointment? See what the numbers say about this price — find out in our valuation breakdown. ASX:MSB P/S Ratio as at Mar 2026Next Steps If this mix of potential and concern feels familiar, it may be a good time to review the data yourself and decide where you stand. Our breakdown of 3 key rewards and 1 important warning sign can help you weigh both sides before you act. Looking for more investment ideas? If Mesoblast has sharpened your focus on where you put your capital next, do not stop here. Use the Simply Wall St screener to line up your next watchlist candidates.  Target potential value opportunities by reviewing our 6 high quality undervalued stocks that pair quality fundamentals with prices that differ from underlying estimates. Strengthen your income shortlist by checking out the 6 dividend fortresses that focus on higher yields with an eye on stability. Prioritise resilience first by scanning the 7 resilient stocks with low risk scores identified by our risk scoring, so you are not the last to spot sturdier names.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}